Quarter Ended

Nine Months Ended

March 31,

2021

2020

2021

2020

Earnings per share – basic:

Net earnings, including noncontrolling interest

$

45,402

$

36,432

$

124,941

$

170,451

Less net earnings (loss) attributable to noncontrolling interest

(380

)

-

(509

)

-

Net earnings attributable to Bio-Techne

$

45,782

$

36,432

$

125,450

$

170,451

Income allocated to participating securities

(27

)

(26

)

(77

)

(126

)

Income available to common shareholders

$

45,755

$

36,406

$

125,373

$

170,325

Weighted-average shares outstanding – basic

38,856

38,303

38,693

38,167

Earnings per share – basic

$

1.18

$

0.95

$

3.24

$

4.46

Earnings per share – diluted:

Net earnings, including noncontrolling interest

$

45,402

$

36,432

$

124,941

$

170,451

Less net earnings (loss) attributable to noncontrolling interest

(380

)

-

(509

)

-

Net earnings attributable to Bio-Techne

$

45,782

$

36,432

$

125,450

$

170,451

Income allocated to participating securities

(27

)

(26

)

(77

)

(126

)

Income available to common shareholders

$

45,755

$

36,406

$

125,373

$

170,325

Weighted-average shares outstanding – basic

38,856

38,303

38,693

38,167

Dilutive effect of stock options and restricted stock units

1,820

1,132

1,612

1,187

Weighted-average common shares outstanding – diluted

40,676

39,435

40,305

39,354

Earnings per share – diluted

$

1.12

$

0.92

$

3.11

$

4.33